1-18. (canceled)
19. A method for treating an inflammatory disease of an eye, the method comprising administering to said eye a stable aqueous liquid preparation that comprises: (a) a first component; and (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 12 hydrate, 1 hydrate, and 32 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation; the second component is tyloxapol and is present in said liquid preparation in an amount sufficient to stabilize said first component; wherein said stable liquid preparation is formulated for ophthalmic administration; and wherein said liquid preparation is administered to said eye at a dose and a frequency effective to treat said inflammatory disease.
20. The method according to claim 19, wherein said inflammatory disease is a disease of an anterior or posterior segment of said eye.
21. The method according to claim 20, wherein said disease is postoperative inflammation.
22. The method according to claim 19, wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt.
23. The method according to claim 19, wherein the concentration of tyloxapol is from about 0.01 wv % to about 0.05 wv %; and wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.01 to about 0.2 wv %.
24. The method according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.02 wv % to about 0.1 wv %.
25. The method according to claim 23, wherein the aqueous liquid preparation further comprises a quaternary ammonium salt.
26. The method according to claim 23, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 wv %.
27. The method according to claim 19, wherein the stable aqueous liquid preparation consists essentially of: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, (d) sodium tetraborate, (e) EDTA sodium salt, (f) benzalkonium chloride, (g) polyvinylpyrrolidone, and (h) sodium sulfite, wherein said liquid preparation is formulated for ophthalmic administration, and wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.02 wv % to about 0.1 wv %.
28. The method according to claim 19, wherein said dose comprises one or two drops.
29. A method for treating an inflammatory disease of an eye, the method comprising administering to said eye a stable aqueous liquid preparation that comprises: (a) a first component; and (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 12 hydrate, 1 hydrate, and 32 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation; the second component is tyloxapol; wherein said stable liquid preparation is formulated for ophthalmic administration; wherein the stable aqueous liquid preparation is characterized in that greater than about 90% of the original amount of the first component remains in the preparation after storage at about 60\xb0 C. for 4 weeks; and wherein said liquid preparation is administered to said eye at a dose and a frequency effective to treat said inflammatory disease.
30. The method according to claim 29, wherein the stable aqueous liquid preparation is characterized in that greater than about 92% of the original amount of the first component remains in the preparation after storage at about 60\xb0 C. for 4 weeks.
31. The method according to claim 29, wherein said inflammatory disease is a disease of an anterior or posterior segment of said eye.
32. The method according to claim 31, wherein said disease is postoperative inflammation.
33. The method according to claim 29, wherein the concentration of tyloxapol is from about 0.01 wv % to about 0.05 wv %; and wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.01 to about 0.2 wv %.
34. The method according to claim 33, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.02 wv % to about 0.1 wv %.
35. The method according to claim 29, further comprising a quaternary ammonium salt
36. The method according to claim 29, wherein the stable aqueous liquid preparation consists essentially of: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 12 hydrate, 1 hydrate, and 32 hydrate; (b) tyloxapol; (c) boric acid; (d) sodium tetraborate; (e) EDTA sodium salt; (f) benzalkonium chloride; (g) polyvinylpyrrolidone; and (h) sodium sulfite; and wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.02 wv % to about 0.1 wv %.
37. A method for treating an inflammatory disease of an eye, the method comprising administering to said eye a stable aqueous liquid preparation that comprises: (a) a first component; and (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 12 hydrate, 1 hydrate, and 32 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation; the second component is tyloxapol; wherein said stable liquid preparation is formulated for ophthalmic administration; provided that the liquid preparation does not include mannitol; and wherein said liquid preparation is administered to said eye at a dose and a frequency effective to treat said inflammatory disease.
38. The method according to claim 37, wherein said inflammatory disease is a disease of an anterior or posterior segment of said eye.
39. The method according to claim 38, wherein said disease is postoperative inflammation.
40. The method according to claim 37, wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt.
41. The method according to claim 40, wherein the concentration of tyloxapol is from about 0.01 wv % to about 0.05 wv % and the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 to about 0.2 wv %.
42. The method according to claim 40, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.02 wv % to about 0.1 wv %.
43. The method according to claim 38; wherein the stable aqueous liquid preparation consists essentially of: (a) 2-amino-3-(4- bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 12 hydrate, 1 hydrate, and 32 hydrate; (b) tyloxapol; (c) boric acid; (d) sodium tetraborate; (e) EDTA sodium salt; (f) benzalkonium chloride; (g) polyvinylpyrrolidone; and (h) sodium sulfite; wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.02 wv % to about 0.1 wv %.
44. The method according to claim 38, wherein the stable aqueous liquid preparation is characterized in that greater than about 90% of the original amount of the first component remains in the preparation after storage at about 60\xb0 C. for 4 weeks.
45. The method according to claim 38, wherein the concentration of tyloxapol is from about 0.01 wv % to about 0.05 wv %; and wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.02 to about 0.1 wv %.
46. The method according to claim 19, wherein the aqueous liquid preparation further satisfies the preservative efficacy standard of EP-criteria B of the European Pharmacopoeia as follows: viable cell counts of bacteria (S. aureus, P. aeruginosa) 24 hours and 7 days after inoculation decrease to not more than 110 and not more than 11000, respectively, and thereafter, the cell count levels off or decreases; and viable cell count of fungi (C. albicans, A. niger) 14 days after inoculation decreases to not more than 110, and thereafter, the cell count keeps the same level as that of 14 days after inoculation.
47. The method according to claim 29, wherein the aqueous liquid preparation further satisfies the preservative efficacy standard of EP-criteria B of the European Pharmacopoeia as follows: viable cell counts of bacteria (S. aureus, P. aeruginosa) 24 hours and 7 days after inoculation decrease to not more than 110 and not more than 11000, respectively, and thereafter, the cell count levels off or decreases; and viable cell count of fungi (C. albicans, A. niger) 14 days after inoculation decreases to not more than 110, and thereafter, the cell count keeps the same level as that of 14 days after inoculation.
48. The method according to claim 37, wherein the aqueous liquid preparation further satisfies the preservative efficacy standard of EP-criteria B of the European Pharmacopoeia as follows: viable cell counts of bacteria (S. aureus, P. aeruginosa) 24 hours and 7 days after inoculation decrease to not more than 110 and not more than 11000, respectively, and thereafter, the cell count levels off or decreases; and viable cell count of fungi (C. albicans, A. niger) 14 days after inoculation decreases to not more than 110, and thereafter, the cell count keeps the same level as that of 14 days after inoculation.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. In a computerized system (i) which includes an interface for connection with a peripheral device and (ii) which is incapable of dynamically extending bus cycle timing if required by the peripheral device in order to carry out a particular current operation, a method comprising;
(a) including within said system a given peripheral device which, during normal operation of the device and under certain circumstances, requires an extension of bus cycle timing in order to carry out properly the current operation in cooperation with said computerized system, said device being configured to generate a specific signal when said extension is required in order to complete carrying out the current operation; and
(b) connecting said given device with the interface of said computerized system and configuring said system in a way which causes the system (i) to recognize said specific signal when the latter is generated and (ii) to instruct the peripheral device to retry carrying out the current operation in response to the presence of said specific signal.
2. A method according to claim 1 wherein said peripheral device is a disk drive.
3. A method according to claim 2 wherein said disk drive includes an ATA interface for connection with the interface of said computerized system and wherein said last-mentioned interface is not an ATA interface.
4. A method according to claim 3 wherein said disk drive is configured to generate an IORDY signal in either an assertion or de-assertion mode, the latter serving as said specific signal whose function is to request a dynamic extension of bus cycle timing of the computerized system when such extension is necessary.
5. A method according to claim 4 wherein said IORDY signal is used in a PIO access mode.
6. A method according to claim 4 wherein the interface of the computerized system is configured to include an interrupt input for receiving an interrupt signal and wherein said disk drive is connected with said last-mentioned interface such that said IORDY signal is applied to said input.
7. A method according to claim 6 wherein said interrupt input is configured as a negative edge sensitive interrupt input.
8. A computerized system, comprising:
(a) a host (i) which includes an interface for connection with a peripheral device and (ii) which is incapable of dynamically extending bus cycle timing if required by the peripheral device in order to carry out a particular current operation;
(b) a given peripheral device which, during normal operation of the device and under certain circumstances, requires an extension of bus cycle timing in order to carry out properly the current operation in cooperation with said computerized system, said device being configured to generate a specific signal when said extension is required in order to complete carrying out the current operation; and
(c) wherein said peripheral device is connected with the interface of said computerized system and wherein said system is configured in a way which causes the system (i) to recognize said specific signal when the latter is generated and (ii) to instruct the peripheral device to retry carrying out the current operation in response to the presence of said specific signal.
9. The system according to claim 8 wherein said peripheral device is a disk drive.
10. The system according to claim 9 wherein said disk drive includes an ATA interface for connection with the interface of said computerized system and wherein said last-mentioned interface is not an ATA interface.
11. The system according to claim 10 wherein said disk drive is configured to generate an IORDY signal in either an assertion or de-assertion mode, the latter serving as said specific signal whose function is to request a dynamic extension of bus cycle timing of the computerized system when such extension is necessary.
12. The system according to claim 11 wherein said IORDY signal is used in a PIO access mode.
13. The system according to claim 11 wherein the interface of the computerized system includes an interrupt input for receiving an interrupt signal and wherein said disk drive is connected with said last-mentioned interface such that said IORDY signal is applied to said input.
14. The system according to claim 13 wherein said interrupt input is a negative edge sensitive interrupt input.
15. In a computerized system including (a) a host (i) which includes an interface for connection with a peripheral device and (ii) which is incapable of dynamically extending bus cycle timing if required by the peripheral device, and (b) a given peripheral device which, during normal operation of the device and under certain circumstances, requires an extension of bus cycle timing in order to carry out properly a particular current operation in cooperation with said computerized system, said device being configured to generate a specific signal when said extension is required in order to complete carrying out the current operation, and (c) wherein the peripheral device is connected with the interface of said computerized system, a method comprising:
configuring said interface in a way which causes the system (i) to recognize said specific signal when the latter is generated and (ii) to instruct the peripheral device to retry carrying out the current operation in response to the presence of said specific signal.
16. A computerized system, comprising:
(a) a host (i) which includes an interface adapted for connection with a peripheral device and (ii) which is incapable of dynamically extending bus cycle timing if required by the peripheral device, said peripheral device being one which, during normal operation of the device and under certain circumstances, requires an extension of bus cycle timing in order to carry out properly a particular current operation in cooperation with said computerized system, said device being one which is configured to generate a specific signal when said extension is required in order to complete carrying out the particular current operation; and
(b) wherein the interface of said computerized system is adapted for connection with said peripheral device, said interface being configured in a way which causes the system (i) to recognize said specific signal when the latter is generated by said peripheral device and the interface is connected with the device and (ii) to instruct the peripheral device to retry carrying out the current operation in response to the presence of the specific signal.